View Older Stories View More Recent Stories
-
Gentherm Incorporated (THRM) PT Lowered to $42 at BMO Capital on 2Q Miss; 'Negatively Affected by Sales Mix & Lower Auto Production'
-
Pandora (P) PT Lowered to $11 at BMO Capital on 2Q Report; 'Listener Hour/Active User Growth Rates Lack Visibility'
-
BMO Capital Starts Criteo S.A. (CRTO) at Outperform
-
Pandora (P) PT Lowered to $11 at BMO Capital
-
Osisko Completes Acquisition of Orion Royalty Portfolio
-
TMI Trust Company Accepts The Trustee And Custody Services Portfolio From BMO Global Asset Management's Family Office Business
-
Form 13F-NT BMO CAPITAL MARKETS CORP For: Jun 30
-
Coca-Cola (KO) PT Raised to $47 at BMO Capital on 2Q Report; 'Encouraging Progress, Despite Rich Valuation'
-
Flowserve Corp. (FLS) PT Raised to $48 at BMO Capital; Stabilizing Pricing & End-Market Activity Continues to Support Recommendation of Shares
-
Pre-Open Stock Movers 07/31: (DVAX) (CHTR) (DAN) Higher; (HTZ) (CLVS) (ICPT) Lower (more...)
-
Industry Leaders Pack Speaker Slate for A&D Strategies Conference and Workshop
-
Mattel Inc. (MAT) PT Lowered to $25 at BMO Capital on 2Q Miss; 'Maintains Guidance... Buying Opportunity for Investors with Longer-Term Horizon'
-
Regeneron (REGN): Sanofi Weakness Could Pressure Shares - BMO
-
Platinum Group Metals Ltd. Operational and Strategic Process Update
-
Contura Energy Inc. (CTRA) Announces 6M Share IPO; Anticipated Price Between $23-$27
-
Contura Announces Launch of Initial Public Offering
-
BMO Capital Upgrades Covanta (CVA) to Outperform
-
BMO Capital Upgrades Wells Fargo (WFC) to Market Perform
-
BMO Capital Downgrades Citi (C) to Market Perform
-
Dollar falls on ECB bets, month-end moves
-
Alexion Pharmaceuticals (ALXN) PT Raised to $168 at BMO Capital on 2Q Beat; 'Upside in Soliris Sales, Upward Revision to Sales Guidance'
-
Celgene (CELG) PT Raised to $160 at BMO Capital; 'Revlimid Gaining Traction in Europe... Growth Should Accelerate Through 2017'
-
ADP (ADP) PT Raised to $105 at BMO Capital on 4Q Report; 'Ackman Bounce Negates Weak Trends'
-
Flowserve Corp. (FLS) PT Lowered to $47 at BMO Capital; '2Q17 Very Poor... Sales, Margin, Earnings Miss, Guidance Lowered'
-
UPDATE: BMO Capital Reiterates Outperform Rating & $1200 PT on Amazon.com (AMZN) 2Q Report; 'Very Strong Revenue Growth, Muted Margins'
-
Starbucks (SBUX) PT Lowered to $64 at BMO Capital on 3Q Report; 'Softer Global Comps & Weaker Operating Margins'
-
Bristol-Myers Squibb (BMY): IO Uncertainty Drives PT Decrease - BMO
-
Tetraphase Pharma (TTPH) Prices 10M Shares at $6.50/Sh
-
Tetraphase Announces Pricing of Public Offering of Common Stock
-
Bristol-Myers Squibb's (BMY) Call Didn't Alleviate Concerns - BMO
-
Sienna Biopharmaceuticals (SNNA) IPO Opens Sharply Higher
-
Vertex Pharma (VRTX): Orkambi Beat Offset By Spending - BMO
-
F5 Networks (FFIV): Staying On The Sidelines - BMO
-
Facebook (FB): Messenger Monetization Begins - BMO
-
Gilead Sciences (GILD): Raising PT To $82 - BMO
-
Mitel Networks (MITL) to acquire ShoreTel (SHOR) for $7.50/Share
-
Mitel announces definitive agreement to acquire ShoreTel
-
Sienna Biopharmaceuticals (SNNA) Prices 4.33M Share IPO at $15/Sh
-
Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
-
Goldcorp Reports Second Quarter 2017 Results
-
Tetraphase Pharma (TTPH) Reports $60M Offering of Common Stock
-
UMH Properties, Inc. Closes Public Offering of 5,000,000 Shares of 6.75% Series C Cumulative Redeemable Preferred Stock
-
Tetraphase Announces Proposed Public Offering of Common Stock
-
Sun Communities, Inc. Reports 2017 Second Quarter Results
-
ULTA Salon (ULTA) Reaction to Violet Grey/Amazon 'Overdone', BMO Says
-
Biogen (BIIB) PT Raised to $328 at BMO Capital; '2Q17 Couldn’t Have Been Better Operationally'
-
Chegg (CHGG) PT Raised to $18 at BMO Capital on 2Q Report; 'Strong Growth Driving Gross Margin Expansion'
-
McDonald's (MCD) PT Raised to $175 at BMO Capital on 2Q; 'Momentum Building Behind Signature Quarter'
-
Interpublic Group (IPG) PT Lowered to $26 at BMO Capital on 2Q Reports
-
Seagate Technology (STX) PT Lowered to $35 at BMO Capital on 4Q Report; 'Market & Operational Issues Amid Management Change'


